Loading organizations...
§ Private Profile · South San Francisco, CA, USA
clinical-stage biotech company developing T cell engager therapeutics for cancer, focused on hematologic cancers and solid tumors.
Amphivena Therapeutics is a clinical-stage immuno-oncology company based in South San Francisco, California, that develops T-cell engager therapeutics for the treatment of blood cancers and solid tumors. The biotechnology firm utilizes its proprietary ReSTORE platform to create dual-function biologics, such as its lead clinical candidate AMV564, which are designed to alleviate immune suppression and stimulate T-cell function against malignant cells. Operating with a small team of fewer than 50 employees, the pre-revenue enterprise funds its clinical research and development pipeline primarily through venture capital and strategic pharmaceutical partnerships. The organization has successfully raised over $80 million in total venture funding to date, including a $62 million Series C financing round backed by prominent investors such as MPM Capital, Qiming Venture Partners, NanoDimension, and Affimed. Amphivena Therapeutics was originally founded in 2013 by entrepreneur Jeanmarie Guenot.
Amphivena Therapeutics has raised $62.0M across 1 funding round.
Amphivena Therapeutics has raised $62.0M in total across 1 funding round.
Amphivena Therapeutics has raised $62.0M in total across 1 funding round.
Amphivena Therapeutics's investors include NanoDimension, Qiming Venture Partners USA, Franklin Berger, AJU IB Investment, Industrial Investors, Kaitai Capital, Korys Merieux, MPM Capital, Nawton Limited, Tekla Capital Management.
Amphivena Therapeutics has raised $62.0M across 1 funding round. Most recently, it raised $62.0M Series C in September 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 24, 2019 | $62M Series C | NanoDimension, Qiming Venture Partners USA | Franklin Berger, AJU IB Investment, Industrial Investors, Kaitai Capital, Korys Merieux, MPM Capital, Nawton Limited, Tekla Capital Management | Announced |